Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2024
DOI:
https://doi.org/10.33321/cdi.2025.49.039Keywords:
antimicrobial resistance, disease surveillance, invasive meningococcal disease, Neisseria meningitidisAbstract
Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
Downloads
References
Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia (CDNA). Invasive Meningococcal Disease: CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; 4 July 2017. Available from: https://www.health.gov.au/resources/publications/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units.
Lahra MM, George RCR, van Hal SJ, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2023. Commun Dis Intell (2018). 2024:48. doi: https://doi.org/10.33321/cdi.2024.48.52.
Lahra MM, George RCR, van Hal SJ, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023:47. doi: https://doi.org/10.33321/cdi.2023.47.44.
Lahra MM, George RCR, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2021. Commun Dis Intell (2018). 2022:46. doi: https://doi.org/10.33321/cdi.2022.46.46.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Communicable Diseases Intelligence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
